Faculty:

Fellow:

Henry Moore-Quiroga, MD (2009-10)

Collaborations:

Clinical Staff:

Clinical Research Staff:

  • Anita Blenke, PA-C, MS, CCRC
  • Marian A. Perez, AA, CCRC
  • Monica Quesada
  • Wendy Levy

Directions to NPF Building

Movement Disorders

The Center for Parkinson’s disease and Movement Disorders (the "Center") is a division of the Department of Neurology within the Leonard M. Miller School of Medicine (MSM) of the University of Miami (UM).  The Center was started in 1984 and has been under the direction of Dr. Carlos Singer since 2002.  It employs four clinical faculty, one Advance Registered Nurse Practitioner, one Licensed Clinical Social Worker, and a support staff of eight.  The Center received the designation as a Center of Excellence from the National Parkinson’s Foundation in 2007. From the time of its inception, the Center’s mission has included patient care, research, education and community outreach. The Center’s core philosophy is patient and caregiver centered. In the area of education, the center emphasizes the values of patient and compassion, a holistic approach to medical care and provision to future health professionals of the basic clinical skills to care for patients with Parkinson’s disease. The Center serves as a tertiary referral center for patients suffering from Parkinson’s disease and other movement disorders in the South Florida community. The Center is also the premier referral center for patients from abroad with a singular projection to Latin America and the Caribbean.

Services Provided:

Parkinson Disease and Movement Disorders Center provides the following services:
  • Specialized medical diagnosis and treatment of Parkinson’s disease and other movement disorders.
  • State of the art neurosurgical therapies including deep brain stimulation for Parkinson’s disease and other movement disorders.
  • Opportunity to participate in research including clinical trials, genetic studies and neuroimaging.
  • Clinical social work case management services.
  • Inpatient consultation services at Jackson Memorial Hospital and Medical Center and the University of Miami Hospital and Clinics.
  • Interdisciplinary Clinic in partnership with St. Catherine’s Rehabilitation Center for patients with Parkinson’s disease. The team consists of a social worker, physiotherapist, occupational therapist, speech therapist and a physician and/or advance registered nurse practitioner. 
  • Community outreach activities including support groups, wellness and exercise sessions, educational seminars for patients, families and health professionals.

Faculty Clinical Research Focus:

  1. Carlos Singer, MD – Nonmotor aspects of Parkinson’s disease.
  2. Bruno V. Gallo, MD – Electrophysiology and neuro-stimulation.
  3. Fatta B. Nahab, MD –  Neuroimaging of movement disorders
  4. Cenk Sengun. MD – Community outreach and patient education.

Links and Publications:

 

Faculty Photo

 

From left to right: Jonathan Jagid M.D.,  Bruno V. Gallo M.D.,
Carlos Singer M.D.,  Cenk Sengun M.D.

    
       
Movement Disorder Studies
Study Description Enrollment Status
 
2CARE Study

The primary hypothesis of the study is that chronic treatment of early-stage HD subjects with high-dosage CoQ will slow the progressive functional decline of HD.

Activley Enrolling
ACADIA 012 Study

The purpose of this study is to evaluate the safety and efficacy of two doses of ACP-103 compared to placebo in the treatment of Parkinson’s Disease psychosis (PDP).

Activley Enrolling
COHORT Study COHORT (Cooperative Huntington Observational Research Trial) is a coordinated research effort by Huntington Study Group research centers worldwide to prospectively collect data from consenting individuals who are affected by Huntington’s disease (HD) and who are part of an HD family.  Activley Enrolling
FJORD Study The primary purpose of the study is to obtain efficacy data and assess safety and tolerability of escalating doses of fipamezole in a population of generally healthy, Hoehn and Yahr Stages 1 through 4, Parkinson’s disease patients.
Activley Enrolling
NET-PD LS-1 Study

The purpose of this study is to determine if creatine is more effective than placebo in slowing the clinical decline in Parkinson's Disease patients with early, treated Parkinson's Disease.

Activley Enrolling
SAD-PD Study The primary objective of this trial is to determine the efficacy of paroxetine and venlafaxine extended release in reducing depressive symptoms in patients with idiopathic Parkinson’s disease (PD). Activley Enrolling
SP921 Study The primary objective of this trial is to show rotigotine dose response (at 2, 4, 6, or 8mg/24h) in subjects with advanced-stage Parkinson’s disease. A secondary objective is to demonstrate the safety and tolerability of rotigotine at these doses. Actively Enrolling